Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Who May Qualify: - Eye with open-angle glaucoma or suspected of open-angle glaucoma - Pseudophakic in eye of interest with Shafer grading ≥3 - ≤ 3 daily applications of topical glaucoma medications for ≥6 months (of which one is a nightly preserved PGA) - Good adherence to medication regimen - screening questions to be asked of potential subject: - In the last month, what percentage of the time would you estimate missing the application of drops? (Must be ≤20%) - When was the last administration? (Last dose must have been within last 24 hours) - Presence of punctate epithelial erosions in the cornea (NEI scale \> 3) Who Should NOT Join This Trial: - Retinal disease (e.g., wet age-related macular degeneration, proliferative diabetic retinopathy, central retinal vein occlusion) - Use of topical or systemic immunosuppressor or immunomodulator drug (e.g., steroids, cyclosporine, lifitegrast, or antihistamines) - Use of preservative-free hypotensive medications - Any clinical contraindications to receiving intracameral bimatoprost implantation - History of recurrent conjunctivitis (e.g., allergic or atopic conjunctivitis) - History of partial or full corneal transplant - History of ophthalmic surgery (intraocular or tarsus-involving oculoplastic procedures) within last 6 months - History of subconjunctival glaucoma surgery (i.e., trabeculectomy, aqueous shunt, Xen implant) within last 6 months Always talk to your doctor about whether this trial is right for you.